Preferred Label : teprotumumab;
Obsolete resource : false;
MeSH note : a fully human IgG1 type monoclonal antibody directed against the human insulin-like
growth factor-I receptor;
CISMeF synonym : R 1507; teprotumumab-trbw;
MeSH hyponym : R1507; R-1507; R-1507 monoclonal antibody; RO-4858696000; RO-4858696; RO4858696-000; RO4858696; RV001;
Is substance : O;
UNII : Y64GQ0KC0A;
Origin ID : C551399;
UMLS CUI : C2987429;
ATC code(s)
Currated CISMeF NLP mapping
MeSH term(s) associated for indexing
Record concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://ansm.sante.fr/tableau-acces-derogatoire/tepezza
2026
false
false
false
France
French
insurance, health, reimbursement
tepezza
teprotumumab
teprotumumab
graves ophthalmopathy
graves disease
myxedema
infusions, intravenous
technical report
drug information
---
https://ansm.sante.fr/tableau-marr/teprotumumab
2026
false
false
false
France
French
risk management
teprotumumab
teprotumumab
antibodies, monoclonal, humanized
tepezza
Product containing only teprotumumab in parenteral dose form (medicinal product form)
drug information
patient education handout
infusions, intravenous
Embryo-foetal toxicity
hearing loss
---
https://www.ema.europa.eu/en/medicines/human/EPAR/tepezza
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
graves ophthalmopathy
adult
infusions, intravenous
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
teprotumumab
teprotumumab
teprotumumab
Product containing only teprotumumab in parenteral dose form (medicinal product form)
receptor, igf type 1
Anti-IGF1R Monoclonal Antibody
product surveillance, postmarketing
pregnancy
drug evaluation, preclinical
drug storage
---
https://www.has-sante.fr/jcms/p_3592956/fr/tepezza-teprotumumab-ophtalmopathie-basedowienne
2025
false
false
false
France
evaluation of the transparency committee
graves ophthalmopathy
tepezza
teprotumumab
---